Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M243Revenue $M4.4Net Margin (%)-967.2Z-Score-3.3
Enterprise Value $M260EPS $-0.8Operating Margin %-1,332.5F-Score2
P/E(ttm))0Cash Flow Per Share $-0.3Pre-tax Margin (%)-1,330.0Higher ROA y-yN
Price/Book15.010-y EBITDA Growth Rate %34.0Quick Ratio3.6Cash flow > EarningsY
Price/Sales41.35-y EBITDA Growth Rate %62.8Current Ratio3.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-91.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)-269.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M73.7ROI % (ttm)-119.2Gross Margin Increase y-yY

Gurus Latest Trades with BTX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

BTX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


BTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SCHLACHET DAVIDDirector 2014-10-08Buy32,050$3.128.97 view
FARRELL STEPHEN CDirector 2014-10-08Buy32,050$3.128.97 view
BROADWOOD PARTNERS LPDirector, 10% Owner 2014-07-22Buy370,000$2.6528.3 view
WEST MICHAEL DCEO 2014-07-22Sell270,000$2.6528.3 view
Peabody RobertSr. VP, COO, and CFO 2014-07-22Sell100,000$2.6528.3 view
TEW WILLIAM P PHDChief Commercial Officer 2014-06-17Sell30,000$3.0710.75 view
BROADWOOD PARTNERS LPDirector, 10% Owner 2014-06-16Buy1,000,000$2.536 view
BROADWOOD PARTNERS LPDirector, 10% Owner 2014-05-16Buy300,000$2.4538.78 view
KINGSLEY ALFRED DSee Remarks, 10% Owner 2014-05-16Sell300,000$2.4538.78 view
KINGSLEY ALFRED DSee Remarks, 10% Owner 2014-05-08Sell300,000$2.4439.34 view

Press Releases about BTX :

    Quarterly/Annual Reports about BTX:

    News about BTX:

    Articles On GuruFocus.com
    Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
    Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

    More From Other Websites
    Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of... Oct 20 2014
    Bloomberg Advantage: ING’s Brzeski, BioTime CEO, Mayor Warren Oct 10 2014
    BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Oct 09 2014
    BioTime, Inc. Closes $31 Million Financing Oct 09 2014
    Asterias Biotherapeutics to List its Series A Common Stock on NYSE MKT Oct 06 2014
    BIOTIME INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,... Oct 06 2014
    Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors Oct 06 2014
    BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Files an IND with the FDA for OpRegen® Designed... Oct 06 2014
    BioTime, Inc. and Subsidiaries to Raise $31 Million Through Sales of Common Shares Oct 06 2014
    BIOTIME INC Financials Oct 04 2014
    BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Oct 03 2014
    BioTime’s Subsidiary OncoCyte Corporation Announces Completion of Multi-Site Clinical Study of... Oct 03 2014
    BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Oct 01 2014
    LifeMap Solutions Adds Chief Technology Officer to Leadership Team Oct 01 2014
    BIOTIME INC Files SEC form 8-K, Other Events Sep 30 2014
    Asterias Biotherapeutics Announces Distribution Date of BioTime Warrants and Conversion Date of... Sep 29 2014
    BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Sep 25 2014
    BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Sep 23 2014
    BioTime, Inc.’s Subsidiary OncoCyte Corporation’s CEO Dr. Joseph Wagner to Present at BTIG’s... Sep 19 2014
    BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Sep 19 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK